Personalis Shares Outstanding 2018-2026 | PSNL
Personalis shares outstanding from 2018 to 2026. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
|
Personalis Annual Shares Outstanding (Millions of Shares) |
|
|---|---|
| 2025 | 89 |
| 2024 | 59 |
| 2023 | 48 |
| 2022 | 46 |
| 2021 | 44 |
| 2020 | 34 |
| 2019 | 18 |
| 2018 | 3 |
| 2017 | 3 |
|
Personalis Quarterly Shares Outstanding (Millions of Shares) |
|
|---|---|
| 2026-03-31 | 104 |
| 2025-12-31 | 89 |
| 2025-09-30 | 89 |
| 2025-06-30 | 89 |
| 2025-03-31 | 87 |
| 2024-12-31 | 59 |
| 2024-09-30 | 61 |
| 2024-06-30 | 52 |
| 2024-03-31 | 51 |
| 2023-12-31 | 48 |
| 2023-09-30 | 49 |
| 2023-06-30 | 48 |
| 2023-03-31 | 47 |
| 2022-12-31 | 46 |
| 2022-09-30 | 46 |
| 2022-06-30 | 46 |
| 2022-03-31 | 45 |
| 2021-12-31 | 44 |
| 2021-09-30 | 45 |
| 2021-06-30 | 44 |
| 2021-03-31 | 42 |
| 2020-12-31 | 34 |
| 2020-09-30 | 35 |
| 2020-06-30 | 32 |
| 2020-03-31 | 31 |
| 2019-12-31 | 18 |
| 2019-09-30 | 31 |
| 2019-06-30 | 7 |
| 2019-03-31 | 3 |
| 2018-12-31 | |
| 2018-09-30 | 3 |
| 2018-06-30 | 3 |
| 2017-12-31 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.630B | $0.070B |
| Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |